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Abstract
Aldehyde dehydrogenases (ALDH) catalyze the irreversible oxidation of aldehydes to their 
corresponding carboxylic acid. Alterations in ALDH1A1 activity are associated with such diverse 
diseases as cancer, Parkinson’s disease, obesity, and cataracts. Inhibitors of ALDH1A1 could aid 
in illuminating the role of this enzyme in disease processes. However, there are no commercially 
available selective inhibitors for ALDH1A1. Here we characterize two distinct chemical classes of 
inhibitors that are selective for human ALDH1A1 compared to eight other ALDH isoenzymes. 
The prototypical members of each structural class, CM026 and CM037, exhibit sub-micromolar 
inhibition constants, but have different mechanisms of inhibition. The crystal structures of these 
compounds bound to ALDH1A1 demonstrate that they bind within the aldehyde binding pocket of 
ALDH1A1 and exploit the presence of a unique Glycine residue to achieve their selectivity. These 
two novel and selective ALDH1A1 inhibitors may serve as chemical tools to better understand the 
contributions of ALDH1A1 to normal biology and to disease states.
INTRODUCTION
Aldehydes are highly reactive compounds that can lead to cellular toxicity through their 
ability to form adducts with a variety of cellular nucleophiles found in proteins, nucleic 
acids, as well as small molecule metabolites. In humans, aldehyde detoxication occurs via 
three main enzyme systems: aldehyde oxidases, aldo-keto reductases, and aldehyde 
dehydrogenases. The human genome contains at least 19 functional genes for aldehyde 
dehydrogenases (ALDH) that catalyze the NAD(P)+-dependent oxidation of endogenous and 
exogenous aldehydes to their corresponding carboxylic acids or CoA esters. ALDHs differ 
in their tissue distribution, subcellular location, structure, as well as preferred substrates and 
are critical enzymes that contribute to numerous biological functions as well as to the 
cellular defense against aldehyde toxicity1. They are involved in the synthesis of critical 
carboxylic acids including retinoic acid, a key regulator of cell growth and development2, 
and the neurotransmitter, γ-aminobutyric acid3. A major role of the ALDH superfamily is 
protection from aldehyde-induced cytotoxicity1. Oxidative stress often results in lipid 
peroxidation, generating over 200 aldehydes, including 4-hydroxyhexenal, 4-
hydroxynonenal, and malondialdehyde4. These endogenously generated compounds can 
carbonylate proteins and have been associated with neurodegenerative disorders5 and 
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aging6. A variety of drugs, including ethanol and the anticancer drug cyclophosphamide, are 
metabolized via ALDH-dependent pathways7. In the environment, although some aldehydes 
have non-anthropogenic sources, motor vehicle exhaust, industrial applications, cigarette 
smoke and other human activities are the primary sources for exogenous aldehydes, 
including formaldehyde, acetaldehyde, and acrolein8.
As a consequence of their critical contributions to aldehyde metabolism, loss of function 
mutations in ALDH genes are linked to a number of diseases. ALDH2 is the primary 
enzyme involved in the oxidation of acetaldehyde during ethanol metabolism9 and a single 
nucleotide polymorphism (SNP) results in an enzymatically crippled protein (ALDH2*2), in 
which acetaldehyde, derived from ethanol oxidation, accumulates and induces alcohol 
toxicity10,11. Alterations in ALDH1A1 and ALDH2 expression or activity may play a role in 
Parkinson’s Disease through the metabolism of the neurotransmitter dopamine, leading to 
increased levels of neurotoxic aldehydes, including 3,4-dihydroxyphenylacetaldehyde12. 
Modulation of ALDH2’s role in dopamine metabolism has been shown to affect cocaine 
seeking behavior13. Mutations in ALDH3A2 lead to Sjögren-Larsson Syndrome, which is 
characterized by mental retardation, icthyosis, and spastic tetraplegia due to impaired 
metabolic clearance of sphingosine and plasmalogen metabolites14,15. Mutations in other 
ALDH genes have been linked to pyridoxine-dependent epilepsy (ALDH7A1)16, type II 
hyperprolinemia resulting in mental retardation and seizures (ALDH4A1 and 
ALDH18A1)17,18, and may possibly contribute to paranoid schizophrenia (ALDH3B1)19. A 
number of ALDHs have been associated with cancer and/or cancer stem cells, including 
ALDH1A1, ALDH1A2, ALDH1A3, ALDH1L1, ALDH2, ALDH3A1, ALDH4A1, and 
ALDH7A17,20. Both ALDH1A1 and ALDH3A1 detoxify some oxazaphosphorine 
anticancer drugs and decrease the drug’s effectiveness21,22. ALDH4A1 is p53- inducible and 
may minimize cellular damage due to oxidative stress23. ALDH1A2 is a possible tumor 
suppressor gene in prostate cancer, likely via the enzyme’s role in retinoid metabolism24. 
The ALDH2*2 mutation has also been associated with a variety of cancers, possibly due to 
increased aldehyde-induced DNA damage25,26. Up-regulation of ALDH activity is also 
common in both normal and cancer stem cells20. Therefore, ALDH is considered a stem cell 
biomarker and the ALDEFLUOR assay (Stemcell Technologies, Vancouver, Canada) uses 
this ALDH activity as a means to identify cancer stem cells27.
ALDH1A1 (retinaldehyde dehydrogenase 1, RALDH1) is a highly conserved, cytosolic 
homo-tetramer (~55 kDa monomers) that is widely expressed and found in numerous 
tissues, including brain, liver, kidneys, adipose, eye lens and retina. A key role of 
ALDH1A1 is the oxidation of retinaldehyde to retinoic acid (RA), forming transcriptional 
regulators critical for normal cell growth and differentiation28. Both the substrate 
(retinaldehyde) and product (RA) are important for normal biological processes, including 
vision, cellular differentiation, and immune function7. ALDH1A1 shares greater than 70% 
sequence identity to both ALDH1A2 and ALDH1A3 (RALDH2 and RALDH3, respectfully) 
and both also convert retinaldehyde to RA, but their roles may be more confined to 
embryogenesis and stem cell development29,30. ALDH1A1 knockout mice are viable, but 
ALDH1A2 and ALDH1A3 knockout mice are lethal early in development or shortly after 
birth30. In addition to its similarity with other retinaldehyde dehydrogenases, ALDH1A1 
also shares nearly 70% sequence identity to the mitochondrial ALDH2 and ALDH1B1 
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enzymes, but shares less than 50% sequence identity with members of other ALDH families, 
including ALDH3A1, ALDH4A1 and ALDH5A1.
The structure of mammalian ALDHs are similar, functioning as homomultimers, and each 
monomer contains three structural domains: a catalytic domain, a cofactor binding domain, 
and an oligomerization domain31. The global structural similarities support identical active 
site residues whose contributions to aldehyde oxidation are well established. In addition to 
aldehyde oxidation activity, some ALDHs, including ALDH1A1, also possess an NAD+-
independent esterase activity32 and this esterase activity uses the same active site residues as 
does the dehydrogenase activity33. Despite similarities in structure and function, as well as 
some overlap in substrate preferences, the isoenzymes of the ALDH family of proteins have 
evolved different aldehyde binding sites due to substitutions of the residues lining their 
respective substrate binding tunnels31,34. These differences have allowed for the 
development of activators and inhibitors of various isoenzymes as therapeutics. For 
example, disulfiram (commercial: Antabuse) is an inhibitor of both ALDH1A1 and ALDH2, 
and this drug can be used to treat alcoholism31 and potentially for cocaine addiction13. 
Alda-1 is a selective activator of ALDH2 and may offer cardiac protection following 
ischemic events by decreasing cytotoxic aldehyde levels35. Since multiple cancers have 
increased ALDH1A1 and/or ALDH3A1 activity leading to increased resistance to 
chemotherapeutic agents, selective inhibitors of these two isoenzymes are also of 
interest36,37.
Available inhibitors of ALDHs have been recently reviewed31. At this time, there are no 
commercially available inhibitors capable of distinguishing between ALDH1A1 and the 
other highly similar ALDH isoenzymes, ALDH1A2, ALDH1A3, ALDH1B1, and ALDH2. 
For instance, the control inhibitor used in the ALDEFLUOR assay, 
diethylaminobenzaldehyde (DEAB), is an effective inhibitor of at least three of these 
isoenzymes38,39. From a high-throughput screen (HTS)40, we have identified two classes of 
ALDH1A1 inhibitors and have determined the structural and kinetic basis for their 
selectivity toward ALDH1A1.
RESULTS
Since the esterase and dehydrogenase activity of ALDH1A1 utilize similar active site 
residues, modulators of esterase function as convenient surrogates for the dehydrogenase 
activity, as has been shown previously with the discovery of ALDH3A1 inhibitors36. The 
esterase assay was selected for the screening assay instead of aldehyde oxidation to: 1.) 
minimize spectral overlap with the absorbance characteristic of the compounds in the 
library, and 2.) eliminate compounds that compete with structurally conserved elements of 
the cofactor binding site. CM026 and CM037 emerged from the HTS as esterase modulators 
of ALDH1A140. CM026 (Figure 1A) has a molecular weight of 442.5 Daltons and CM037 
(Figure 2A) has a molecular weight of 431.6 Daltons. These compounds have no structural 
similarity to any known, commercially available aldehyde dehydrogenase modulators.
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Kinetic characterization of CM026 and CM037
CM026 is a selective inhibitor for ALDH1A1 versus eight other ALDH isoenzymes 
examined. At a concentration of 20 µM, CM026 had no effect on seven other human ALDH 
isoenzymes (ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH4A1, 
ALDH5A1) as well as the carboxyl-terminal ALDH domain of rat ALDH1L1 (Figure 1B). 
At a concentration of 100 µM, CM026 modestly increased aldehyde oxidation catalyzed by 
ALDH1A2, ALDH1A3, and ALDH1B1. CM026 has good potency toward ALDH1A1 (IC50 
of 0.80 ± 0.06 µM40, Figure 1C) for an initial hit compound. Complete inhibition of 
ALDH1A1 was not observed. CM026 has a noncompetitive partial mode of inhibition with 
respect to varied acetaldehyde, with a Ki of 0.80 ± 0.16 µM and β = 0.15 ± 0.03, indicating 
maximum inhibition at 0.15(Vmax) (Figure 1D). CM026 had an uncompetitive partial mode 
of inhibition with respect to varied NAD+ and exhibited a Ki of 0.72 ± 0.03 µM and β = 0.10 
± 0.03 (Figure 1E).
It is possible that the size of the R-groups attached to the xanthine ring influences whether it 
is possible to slowly bind and release small aldehydes at the catalytic nucleophile, such 
substrate length dependency was also observed with the activator Alda-1 in ALDH241.
CM037 (Figure 2A) was also selective for ALDH1A1 at 20 µM versus eight other ALDH 
isoenzymes tested (Figure 2B). While 20 µM CM037 had little effect on most ALDH 
isoenzymes tested, ALDH1A3 was inhibited approximately 20% at this concentration. 
Higher concentrations were not tested due to solubility limits of CM037 under these assay 
conditions. CM037 exhibits an IC50 = 4.6 ± 0.8 µM toward ALDH1A1 versus the substrate 
propionaldehyde (Figure 2C) and a competitive mode of inhibition with respect to varied 
substrate acetaldehyde and an average Ki of 0.23 ± 0.06 µM from three independent 
inhibition experiments42.
Structure Activity Relationship for Analogs of CM026
There were 77 compounds in the initial screening hit list that were structurally similar to 
CM02640. We have tested 17 members of this compound class and they exhibit good 
selectivity for ALDH1A1 compared to ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and 
ALDH3A1 (Table 1). At high concentrations (100 µM), some compounds activated the 
aldehyde oxidation activity of other ALDH1 enzymes tested (eg. CM026), but in most cases 
these effects were observed as the solubility limit of the compounds in the assay system 
were approached, precluding a full dose-response study. At 20 µM, none of the compounds 
demonstrated activation exceeding 10% of control activity, suggesting any activation is of 
modest potency and not likely to impact these enzyme activities in vivo. These compounds 
share a common xanthine core structure with theophylline and caffeine, but neither of these 
stimulants affected ALDH1A1 activity at concentrations up to 250 µM, indicating that 
substituents at the R1 and R2 positions are necessary for ALDH1A1 inhibition (Table 1). 
Halogens on either R-group were not tolerated. CM053 was the most potent analog 
examined, with an IC50 = 210 ± 40 nM and a Ki = 96 ± 14 nM with noncompetitive tight 
mode of inhibition compared to varied substrate acetaldehyde (Figure 3). CM028 shares the 
same R2 group as CM053 but the isopentyl group at R1 has been replaced with a 
phenylpropyl group. CM028 is less potent, with an IC50 = 2.0 ± 0.1 µM, and exhibits a Ki = 
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240 ± 40 nM with competitive tight mode of inhibition. The lower potency suggests that the 
phenylpropyl group might present steric conflicts not found with the smaller phenyl and 
isopentyl groups (Table 1). Unlike CM026, CM028 and CM053 demonstrated complete 
inhibition, which confirms that the nature of the R1 group alone does not influence the final 
extent of inhibition, since both CM026 and CM053 share the same R1 group.
Crystal Structure of ALDH1A1 Complexed with CM026, CM053 and CM037
To determine the mechanism that underlies the ability of these compounds to selectively 
inhibit ALDH1A1, we used X-ray crystallography to determine the structure of the enzyme-
compound complexes. We solved the crystal structures of human ALDH1A1 in complexes 
with CM026, CM053, and CM037 to resolutions between 1.80 Å and 1.95 Å (Table 2). For 
CM026 and CM037, the naturally occurring N121S polymorphic variant of ALDH1A1 was 
used40, while wtALDH1A1 was used for the structure with bound CM053. A comparison of 
the respective alpha carbons in the structure of the N121S·CM026 to those in the 
WT·CM053 generated an RMSD of 0.12Å, indicating a high degree of similarity between 
WT and the N121S mutant as expected since the two have very similar kinetic behavior40. 
CM026 binds near the solvent exposed exit of the substrate-binding site (Figure 4). The 
xanthine rings for both CM026 and CM053 are parallel to and approximately 3.6 Å from 
Tyr297, with which it interacts via hydrophobic pi-stacking interactions. Four residues form 
hydrogen bonds with CM026; the xanthine ring interacts with His293, Cys302, and Gly458, 
while Trp178 interacts with the ketone group on R2. The isopentyl group of R1 projects 
towards Cys303 and fills much of the hydrophobic space bounded by Phe171 and Phe466. 
CM053 differs from CM026 only in its R2 group, which can form hydrogen bonds with two 
residues, Trp178 and Val460 (Figure 5). CM037 binds at a similar location to the CM026 
compounds, but its long axis is oriented almost orthogonal to that of CM026 and CM053 
(Figure 6A). Most of the tricyclic ring of CM037 is in a hydrophobic pocket formed by 
Phe171, Val460, and Phe466 with a potential hydrogen bond between the ring system’s 
carbonyl oxygen atom and the side chain of Cys302 (Figure 6B). The biggest structural 
adaptation to CM037 binding is the movement of Trp178 away from the substrate-binding 
site to accommodate the benzyl ring of CM037 (Figure 6C). This conformational movement 
appears to be dynamic and impacts the observed electron density for both the benzyl group 
of CM037 and of Trp178. Trp178 is well ordered in all other structures determined of 
human ALDH1A, including our CM026 and CM053 structures, but has weak density for the 
benzyl moiety of the indole ring in this complex (Figure 6D). We would suggest that 
optimization of CM037 could be achieved by altering the thiophene and benzyl ring systems 
to alleviate these steric conflicts. To better understand the selectivity of these compounds for 
ALDH1A1, we compared these structures against human ALDH2 (PDB code 1CW343), 
ALDH3A1 (PDB code 3SZA37), and ALDH4A1 (PDB code 3V9G44) and identified a 
critical glycine (Gly458) that is present near the xanthine ring binding site in ALDH1A1. 
This glycine is replaced by larger amino acid side chains in the other three human structures 
examined, as well as in sheep ALDH1A1 (PDB Code 1BXS45). In rat ALDH1A2 (PDB 
code 1BI946), which shares 97% sequence identity to human ALDH1A2, this location is part 
of a small disordered loop not observed in the crystal structure46. Using sequence 
alignments of the human genes, Gly458 in ALDH1A1 is replaced by an asparagine in 
ALDH1A2, ALDH1A3, and ALDH1B1, an aspartate in ALDH2, and an isoleucine in 
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ALDH3A1 (Figure 7A). As shown in Figure 7B, these side chains would interfere with the 
position of the xanthine ring, effectively eliminating the ability of these analogs to bind to 
any isoenzyme but ALDH1A1.
Characterization of ALDH1A1 G458N Mutant
To confirm whether Gly458 in ALDH1A1 directly impacts the selectivity of the CM026 
analogs and CM037 for ALDH1A1, we mutated the glycine at this position to asparagine, as 
found in ALDH1A2 and ALDH1A3. We determined the kinetic parameters for acetaldehyde 
oxidation for both the wild-type and G458N enzymes (Table 3). This mutation did not 
dramatically affect the enzyme’s catalytic efficiency for aldehyde oxidation. However, when 
Gly458 is mutated to asparagine, CM026 no longer inhibits the enzyme at concentrations up 
to 100 µM and none of the CM026 analogs inhibited the mutant more than 25% (Figure 8). 
Similarly, 20 µM CM037 no longer inhibited the G458N enzyme. However, the non-
selective inhibitors DEAB and CM30240 both inhibit G458N, with IC50 values of 0.52 ± 
0.10 µM and 3.1 ± 0.3 µM respectively39,40 (Table 3). These data support the hypothesis that 
the substrate-binding site, and in particular Gly458, determines the selectivity of both the 
CM026 and CM037 classes of compounds for ALDH1A1, and that bulkier side chains at 
this position in ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and ALDH3A1 occludes their 
binding to these ALDH isoenzymes.
DISCUSION AND CONCLUSIONS
Aldehyde dehydrogenases contribute to a variety of biological processes and disease states. 
ALDH1A1, in particular, has been linked to such diverse diseases as cancer, Parkinson’s 
disease, obesity, and cataracts. Therefore, selective inhibitors of ALDH1A1 would be of 
tremendous value to understanding the roles of this enzyme in both normal and disease 
processes. However, great structural and functional similarity exists, especially within the 
ALDH1 family, with five members sharing approximately 70% protein sequence identity or 
higher, plus significant overlap in substrate utilization. To date, there are no ALDH1A1-
selective inhibitors commercially available. Although comparisons of available ALDH 
structures indicate a high degree of overlap, there exist distinct surface topographies that 
may enable development of selective inhibitors (Figure 9). ALDH1A1 possesses a wider 
opening leading to the active site, whereas ALDH2 has a much more constricted, cylindrical 
shaped site. ALDH3A1 possesses a wider inner vestibule near the catalytic nucleophile, with 
a much narrower and curved entryway. The narrower entries in ALDH2 and ALDH3A1 
eliminate the binding site for the CM026 and CM037 classes of inhibitors in large part due 
to the side chain present at the position equivalent to Gly458. ALDH4A1 possess a serine at 
the position equivalent to Gly458. However the loop structure in which it resides is different 
enough from ALDH1A1 to prevent compound binding. Similar to daidzin, both the CM026 
and CM037 classes of compounds are planar, multi-ringed structures that adopt binding 
modes that take advantage of the topological characteristics unique to the ALDH isoenzyme 
toward which they demonstrate selectivity and neither of these new compounds can be 
accommodated in the restricted substrate binding sites of ALDH3A1 or ALDH2. Daidzin is 
a strong inhibitor of ALDH2 but it also inhibits ALDH1A147. Daidzin binds in a similar 
location to CM026, but comparison of the structure of ALDH1A1 and ALDH2 (PDB 
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2VLE48) bound to these respective compounds shows that the two compounds bind nearly 
perpendicular to each other in their respective binding modes. In particular, aligning the 
ALDH2-daidzin structure to ALDH1A1 demonstrates that daidzin binding need not engage 
ALDH1A1 near its unique G458 site (Figure 10). As discussed by Lowe et al, the tighter 
binding pocket of ALDH2 compared to ALDH1A1 favors more intimate interactions 
between the ALDH2 and daidzin, increasing specificity48. CM026 exploits a binding pocket 
that is not accessible in other ALDH isoenzymes due to their larger amino acid side chains 
at position 458.
In contrast to CM026, the directionality of CM037 binding within the ALDH1A1 active site 
resembles that of daidzin in ALDH2. However, the 4-oxo group and the branched structure 
of CM037 near the exit of the substrate binding site exploits the same G458 region for 
selectivity. Our structural studies identified Gly458 as a major contributor to the selectivity 
of the CM026 and CM037. Sequence alignments of the other 18 human ALDH isoenzymes 
indicate that the only other family member with a glycine in this position is ALDH16A1. 
However, the function of ALDH16A1 is unknown and has a three residue deletion in the 
active site loop which eliminates the conserved Cys nucleophile, suggesting this protein may 
have functions that are independent of aldehyde dehydrogenase activity49. The presence of a 
non-glycine residue at this position does not adversely affect catalytic activity toward small 
substrates or inhibition by the non-selective compounds, DEAB and CM302. Consequently, 
these compounds identified via an esterase-based high throughput screen successfully 
exploited a unique structural feature found primarily in primate ALDH1A1 enzymes, which 
further validates the use of the esterase activity as a screening tool for ALDH isoenzymes40.
Selective inhibitors of ALDH1A1 are needed to understand the role of this enzyme in both 
normal and disease processes. As recently reviewed by Ma and Allan, a number of ALDH 
family members have been associated with both normal stem cells and cancer stem cells20. 
The viability of the ALDH1A1-/- mice suggests that ALDH1A1 is non-essential or can be 
compensated for by other family members during growth and development50. On the other 
hand, ALDH1A1 is considered a biomarker for lung51, ovarian52, prostate53 and a number 
of other cancers. Ovarian cancer cells form spheroids, cellular aggregates that aid 
metastasis54. Recently ALDH1A1 was shown to be upregulated in ovarian cancer 
spheroids42. This study utilized our ALDH1A1- selective compound CM037 (published as 
A37) to disrupt spheroid formation and reduce cell viability, supporting the hypothesis that 
ALDH1A1 could serve as a target to improve cancer outcomes42. ALDH1A1 and 
ALDH3A1 are both involved in the metabolism of the cancer drug cyclophosphamide, 
metabolizing the active compound to a less active form and contributing to drug resistance. 
ALDH3A1 inhibitors have been shown to increase sensitivity to the cyclophosphamide 
analog mafosphamide when combined in cell lines with high ALDH3A1 expression55,56. 
ALDH1A1 could serve as a similar target to minimize cyclophosphamide resistance in 
cancers with high ALDH1A1 levels. The functional role that ALDH1A1 contributes to stem 
cells and cancer metastasis is not understood. However, the discovery of these two novel 
classes of selective ALDH1A1 inhibitors may serve as chemical tools to uncover those roles 
in both normal and diseased cells.
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EXPERIMENTAL SECTION
Materials
Reagents, including acetaldehyde, propionaldehyde, para-nitrophenylacetate, NAD+, and 
buffers were all purchased from Sigma Aldrich unless otherwise noted. Compounds were 
purchased from ChemDiv Corp. (San Diego, CA) and were >95% pure based on the NMR 
spectra provided by the vendor. Following receipt from the vendor, their chemical identities 
were further verified by LC/MS in the Department of Chemistry, Indiana University-Purdue 
University Indianapolis and used without further purification.
ALDH expression and purification
ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and ALDH3A1 were produced 
and purified as previously described36,56,57. The ALDH1A1 protein used for the 
ALDH1A1-CM026 crystal contained an Asn-to-Ser SNP at residue 12140,58. Unless where 
noted otherwise, ALDH1A1 WT protein was used for all aldehyde oxidation assays and for 
the ALDH1A1- CM053 structure. The full length cDNA for human ALDH4A1 and 
ALDH5A1 were generously provided by Daria Mochly-Rosen. ALDH4A1 was subcloned 
into the pET-28a expression plasmid and ALDH5A1 was in pTrcHis-Topo. The carboxyl 
terminal ALDH domain of rat ALDH1L1 was generously provided by Sergey Krupenko in 
the pRSET expression plasmid. ALDH1L1, ALDH4A1, and ALDH5A1 were expressed and 
purified as previously described for ALDH3A136 with the following modifications: 1) for 
ALDH1L1 and ALDH5A1 the medium contained 100 µg/mL ampicillin, 2) cells were lysed 
via 3 passages through a microfluidizer (DivTech Equipment), and 3) a single passage on a 
nickel-NTA column was used for purification, without the second Q-sepharose column used 
to purify ALDH3A1. Purified enzymes used for kinetics were stored at −80°C. ALDH1A1 
used for crystallization was stored at −20°C in a 50% (v/v) solution with glycerol and 
dialyzed against 10 mM Na+-ACES pH 6.6 and 1 mM dithiothreitol at 4°C.
Generation of wild-type ALDH1A1 and the G458N mutant
The QuikChange site-directed mutagenesis protocol was used to make point mutations. 
First, wtALDH1A1 was generated from the Weiner N121S polymorphism as previously 
described40. A point mutation of wtALDH1A1 was performed to produce the G458N 
mutant. The ALDH1A1 G458N mutant was constructed using the forward primer 5’-GTG 
GGT GAA TTG CTA TAA CGT GGT AAG TGC CCAG-3’ and its complement. This 
G458N mutant was purified in the same way as other ALDH1A1 proteins (WT, N121S). 
G458N was stored at 2-mg/mL and 8-mg/mL at −80°C. Kinetic experiments for G458N 
were performed in the same manner as WT protein.
Aldehyde dehydrogenase activity assay
Dehydrogenase activity of purified recombinant ALDH1A1, ALDH1A2, ALDH1A3, 
ALDH1B1, ALDH2, and ALDH3A1 was assayed spectrophotometrically by monitoring the 
formation of NADH at 340 nm (molar extinction coefficient of 6220 M−1 cm−1) on a 
Beckman DU-640 or Cary 300 Bio UV-Vis spectrophotometer. Characterization of 
ALDH1A1 WT and ALDH1A1 G458N were performed by co-varying acetaldehyde and 
Morgan and Hurley Page 8
J Med Chem. Author manuscript; available in PMC 2016 February 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
NAD+ concentrations in reactions containing 150 – 300 nM enzyme, 50 – 500 µM or 20 – 
200 µM acetaldehyde, and 50 – 500 µM NAD+ in 50 mM sodium BES, pH 7.5 at 25°C. 
Reactions were initiated by adding enzyme. Selectivity of compounds for dehydrogenase 
activity of ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1 and ALDH2 were measured in a 
solution containing 100 – 200 nM enzyme, 200 µM NAD+, 1% DMSO, and 100 µM 
propionaldehyde (non-saturating for all enzymes tested, except ALDH2) in 50 mM sodium 
BES. ALDH3A1 activity was measured under the following conditions: 25 nM enzyme, 200 
µM NAD+, 1% DMSO, and 300 µM benzaldehyde (~KM) in either 100 mM sodium 
phosphate buffer, pH 7.5 or 50 mM sodium BES, pH 7.5. All assays were performed at 
25°C and were initiated by the addition of the aldehyde substrate following a 2 minute pre-
incubation with compound and cofactor. Selectivity was initially tested using 20 µM 
compound, with ALDH1A1-selective modulators further tested using 100 µM compound. 
IC50 values for propionaldehyde oxidation were calculated by varying the concentration of 
the compounds from 0 to 200 µM. After a 2 minute pre-incubation with compound and 
NAD+, all reactions were initiated by the addition of propionaldehyde. Data were fit to the 
four parameter EC50 equation using SigmaPlot (StatSys v12.3). The values represent the 
average of three independent experiments (each n = 3). The mode of inhibition was 
determined via steady-state kinetics by co-varying inhibitor and substrate concentrations at 
fixed concentration of the second substrate. All reactions contained 100–150 nM ALDH1A1 
and 1% DMSO in 50 mM sodium BES, pH 7.5 at 25°C. When cofactor NAD+ was varied, 
the reactions contained 200 µM propionaldehyde and 20 – 200 µM or 25 – 250 µM NAD+ 
(Km = 50 µM). When acetaldehyde was varied, the reactions contained 800 or 1000 µM 
NAD+ and 100 – 800 µM acetaldehyde (Km = 180 µM). All data were fit to competitive, 
noncompetitive, uncompetitive, and mixed inhibition models using both single substrate-
single inhibitor or tight binding inhibition programs in SigmaPlot (StatSys v12.3). The 
appropriate model was selected through analysis of goodness-of-fit and the residuals of 
those fits. The values represent the average of three independent experiments (each n = 3) 
using at least two protein preps. In Sigmaplot, the data were best fit to the following 
equations:
Morgan and Hurley Page 9
J Med Chem. Author manuscript; available in PMC 2016 February 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Crystallization and structure determination of ALDH1A1 and its complexes with inhibitors
Crystals of ALDH1A1 at 3–5 mg/mL concentration were equilibrated against a 
crystallization solution of 100 mM Na+ BisTris, pH 6.2–6.8, 8–12% PEG3350 (Hampton 
Research), 200 mM NaCl, and 5–10 mM YbCl3 at 25°C. For the enzyme·CM026 and 
enzyme·CM037 complex, ALDH1A1·N121S was used, while wtALDH1A1 was used for 
the ALDH1A1·CM053 complex. CM026 and CM053 complexes were prepared by soaking 
crystals overnight with crystallization solution containing 500 µM inhibitor with 2% (v/v) 
DMSO. The CM037 complex was prepared by soaking crystals with crystallization solution 
containing 500 µM inhibitor, 1% (v/v) DMSO, and 1 mM NAD+ for 5 hours. Cryo-
protection of the crystals for flash-freezing utilized 20% (v/v) ethylene glycol in the ligand 
soaking solution. Diffraction data were collected at Beamline 19-ID for the ALDH1A1-
CM026 complex and Beamline 19-BM for the ALDH1A1-CM053 complex, both operated 
by the Structural Biology Consortium at the Advanced Photon Source (APS), Argonne 
National Laboratory. For the ALDH1A1-CM037 complex, data were collected at Beamline 
23-ID-D (GM/CA), sponsored by National Institute of General Medical Sciences and 
National Cancer Institute of the National Institutes of Health at APS. All diffraction data 
were indexed, integrated, and scaled using either the HKL2000 or HKL3000 program 
suites59. The CCP4 program suite60 was used for molecular replacement and refinement, 
using human apoALDH1A1 structure (PDB code 4WJ9) as a model for both structures. The 
molecular graphics application Coot61 was used for model building and TLSMD 
(Translation/Libration/Screw Motion Determination) server was used to determine the 
appropriate TLS tensors for refinement of the protein62,63.
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Abbreviations Used
ACES N-(2-Acetamido)-2-aminoethanesulfonic acid
ALDH aldehyde dehydrogenase
BES N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid
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BisTris 2-Bis(2-hydroxyethyl)amino-2-(hydroxymethyl)-1,3-propanediol
RA retinoic acid
RALDH retinaldehyde dehydrogenase
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Figure 1. 
Characterization of CM026, a selective inhibitor of ALDH1A1. (A) The structure of 
CM026. (B) Selectivity of 20 µM of CM026 with respect to nine ALDH isoenzymes. (C) 
IC50 of CM026 with ALDH1A139. (D) Lineweaver-Burk representation of noncompetitive 
inhibition for CM026 (0 – 4 µM) verses varied acetaldehyde (100 – 800 µM) at fixed 
concentration of NAD+ (800 µM). (E.) Lineweaver-Burk representation of uncompetitive 
inhibition for CM026 (0 – 3 µM) verses varied NAD+ (25 – 250 µM) at fixed concentration 
of propionaldehyde (200 µM). The IC50 curves and Lineweaver-Burk plots represent one of 
three experiments performed for each condition, with each point the mean/SEM of three 
data points at each concentration.
Morgan and Hurley Page 15
J Med Chem. Author manuscript; available in PMC 2016 February 26.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. 
Characterization of CM037, a selective inhibitor of ALDH1A1. (A) The structure of CM037 
with a molecular weight of 431.6 Daltons. (B) Selectivity of 20 µM of CM037 with respect 
to nine ALDH isoenzymes. (C) IC50 of CM037 with ALDH1A142. The IC50 curve 
represents one of three experiments performed, with each point the mean/SEM of three data 
points at each concentration.
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Figure 3. 
Characterization of CM053. (A) IC50 of CM053 with ALDH1A1. (B) Lineweaver-Burk 
representation of noncompetitive tight inhibition for CM053 (0 – 300 nM) verses varied 
acetaldehyde (100 – 800 µM) at fixed concentration of NAD+ (1000 µM). Both curves 
represent one of three experiments performed, with each point the mean/SEM of three data 
points at each concentration.
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Figure 4. 
Structure of ALDH1A1 N121S with CM026 (PDB Code 4WP7). (A) CM026 binds in the 
active site near Cys 303. Key residues are colored based on element, and Gly458 is shown in 
orange. (B) Two-dimensional representation of the key hydrogen bonds, illustrated with red 
dashed lines, and hydrophobic interactions, illustrated with black arcs, between ALDH1A1 
and CM026. (C) The electron density maps of CM026, with the original Fo – Fc map in 
green contoured at 2.5 standard deviations and the final 2Fo – Fc map in grey contoured at 
1.0 standard deviations. Figures A and C generated in Pymol, while Figure B generated in 
ChemDraw.
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Figure 5. 
Structure of human ALDH1A1 with CM053 (PDB Code 4WPN). (A) Two dimensional 
representation of the key hydrogen bonds, illustrated with red dashed lines, and hydrophobic 
interactions, illustrated with black arcs, between ALDH1A1 and CM053. (B) The electron 
density maps of CM053 with the original Fo – Fc map in green contoured at 2.5 standard 
deviations and the final 2Fo – Fc map in grey contoured at 1.0 standard deviations. Figure A 
generated in ChemDraw and figure B generated in Pymol.
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Figure 6. 
Structure of ALDH1A1 N121S with CM037 (PDB Code 4X4L). (A) CM037 binds in the 
active site near Cys 303. Key residues are colored based on element, and Gly458 is shown in 
orange. (B) Two-dimensional representation of the hydrophobic interactions, illustrated with 
black arcs, between ALDH1A1 and CM037. (C) Binding of CM037 induces structural 
changes in ALDH1A1 (in blue) compared to apo-ALDH1A1 (in gray), particularly at W178. 
NADH binding (in cyan), induces conformational changes at the cofactor binding site, as 
seen here with E269. (D) The electron density maps of CM037, with the original Fo – Fc 
map in green contoured at 2 standard deviations and the final 2Fo – Fc map in grey 
contoured at 1.0 standard deviations. Figures A, C and D generated in Pymol, while Figure 
B generated in ChemDraw.
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Figure 7. 
Structural basis of selectivity of CM026 for ALDH1A1. (A) Multiple sequence alignment in 
the region of ALDH1A1 Gly458 to the mature form of ALDH2. (B) Structure of ALDH1A1 
with bound CM026 (blue) compared to ALDH2 (cyan) and ALDH3A1 (grey) indicating that 
a bulky amino acid such as the Asp of ALDH2 and Ile of ALDH3A1 would clash with 
CM026 and prevent the compound from inhibiting the enzyme. Sequence alignment was 
performed using NCBI delta-BLAST while structural alignment was performed using least 
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square fit (LSQ) in Coot. Figure B generated in Pymol. PDB Codes: ALDH1A1 (4WP7), 
ALDH2 (2VLE), and ALDH3A1 (3SZA)
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Figure 8. 
Selectivity of compounds for WT vs G458N mutant. For CM026 and its analogs, 100 µM of 
compound was used. For CM037 and CM302, 20 µM of compound was used. Each value is 
mean/SEM (n=3).
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Figure 9. 
Comparison of the active site topography of human ALDH1A1, ALDH2, and ALDH3A1. 
The three isoenzymes were aligned using LSQ in Coot and the surface figures generated via 
Pymol. The active site cysteine is shown in red for all three isoenzymes. G458 in ALDH1A1 
(PDB Code 4WJ9) and its equivalent residues D457 in ALDH2 (PDB Code ICW3) and I391 
in ALDH3A1 (PDB Code 3SZA) are shown in yellow.
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Figure 10. 
Comparison of the binding of CM026 to ALDH1A1 (PDB Code 4WP7) with the binding of 
daidzin to ALDH2 (PDB Code 2VLE). ALDH1A1 is shown in light blue with CM026 in 
dark blue. ALDH2 is shown in light green with daidzin in dark green. The active site 
cysteine is shown in red for both isoenzymes. Although both compounds bind in the same 
location, they bind in a different orientation enabling CM026 to inhibit ALDH1A1 but not 
ALDH2 due to steric hindrance of D474 (D457 in the mature sequence, in orange), while 
daidzin inhibits both isoenzymes. Figure generated in Pymol.
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Table 2
Data collection and refinement statistics.
Data Collection
ALDH1A1-
CM026
PDB 4WP7
ALDH1A1-
CM053
PDB 4WPN
ALDH1A1-
CM037
PDB 4X4L
Space Group P422 P422 P422
Cell Dimensions
    a, b, c (Å) 109, 109, 83 109, 109, 83 109, 109, 83
    A,β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90
Resolution (Å) 50 – 1.80 50 – 1.95 50 – 1.85
Rmerge 0.082 (0.59) 0.11 (0.66) 0.058 (0.70)
I/σi 22.7 (4.7) 18.3 (3.7) 27.4 (3.3)
Completeness (%) 99 (100) 99 (100) 99 (100)
Redundancy 11.7 (11.7) 9.3 (6.9) 8.5 (8.8)
Refinement
No. of Reflections 44544 35048 40517
Rwork/Rfree 0.19 / 0.22 0.19 / 0.24 0.19 / 0.22
No. of Atoms 4109 4080 4066
    Protein 3833 3858 3806
    Ligand/Ion 35 33 80
    Water 241 189 180
R.M.S. Deviations
    Bond Lengths (Å) 0.008 0.009 0.010
    Bond Angles (°) 1.28 1.30 0.135
Numbers in parenthesis represent values of highest resolution shell.
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